Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields

During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.

Below are the ratings of the most accurate analysts for three high-yielding stocks in the healthcare sector.

Bristol-Myers Squibb Company BMY

• Dividend Yield: 5.82%
• BMO Capital analyst Evan Seigerman maintained a Market Perform rating and cut the price target from $55 to $48 on April 26. This analyst has an accuracy rate of 62%.
• Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and raised the price target from $51 to $52 on April 18. This analyst has an accuracy rate of 77%.
• Recent News: A judge in Hawaii has reportedly ordered Bristol Myers Squibb and Sanofi SA SNY to pay the state over $916 million for failing to warn non-white patients about health risks associated with their blood thinner Plavix.

Pfizer Inc. PFE

• Dividend Yield: 5.82%
• Morgan Stanley analyst Terence Flynnmaintained an Equal-Weight rating and raised the price target from $28 to $29 on May 2. This analyst has an accuracy rate of 70%.
• Argus Research analyst David Toungdowngraded the stock from Buy to Hold on March 22. This analyst has an accuracy rate of 68%.
• Recent News: Pfizer has recently launched a multi-year cost reduction initiative aimed at saving approximately $1.5 billion by the end of 2027.

CVS Health Corporation CVS

• Dividend Yield: 4.79%
• Wells Fargo analyst Stephen Baxter maintained an Equal-Weight rating and cut the price target from $76 to $60 on May 7. This analyst has an accuracy rate of 64%.
• UBS analyst KevinCaliendodowngraded the stock from Buy to Neutral and slashed the price target from $85 to $60 on May 2. This analyst has an accuracy rate of 71%.
• Recent News: CVS Health is reportedly seeking a private equity partner to fund the expansion of Oak Street Health, the $10.6 billion primary care provider it acquired last year.

Read More: GameStop, Box And 3 Stocks To Watch Heading Into Tuesday